Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL IMMUNOLOGY
Volume 32, Issue 3, Pages 632-646
Publisher
Springer Nature
Online
2012-02-08
DOI
10.1007/s10875-011-9624-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease
- (2011) D. Bagnara et al. BLOOD
- Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia
- (2011) Issa F. Khouri et al. CANCER
- Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition
- (2011) E. Mamessier et al. CANCER RESEARCH
- Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
- (2011) Emilie Mamessier et al. JOURNAL OF CLINICAL INVESTIGATION
- Update on Therapy of Chronic Lymphocytic Leukemia
- (2011) John G. Gribben et al. JOURNAL OF CLINICAL ONCOLOGY
- CD56brightCD16+ NK Cells: A Functional Intermediate Stage of NK Cell Differentiation
- (2011) V. Beziat et al. JOURNAL OF IMMUNOLOGY
- Innate or Adaptive Immunity? The Example of Natural Killer Cells
- (2011) E. Vivier et al. SCIENCE
- The clinical application of monoclonal antibodies in chronic lymphocytic leukemia
- (2010) S. M. Jaglowski et al. BLOOD
- Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education
- (2010) N. K. Bjorkstrom et al. BLOOD
- State of the art treatment of chronic lymphocytic leukaemia
- (2010) Michael Hallek et al. BLOOD REVIEWS
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
- (2010) M Le Garff-Tavernier et al. LEUKEMIA
- Alloreactive natural killer cells in hematopoietic stem cell transplantation
- (2010) Hollie J. Pegram et al. LEUKEMIA RESEARCH
- Prognostic factors in chronic lymphocytic leukemia—what do we need to know?
- (2010) Paula Cramer et al. Nature Reviews Clinical Oncology
- Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN- on activation
- (2010) A. De Maria et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression
- (2009) S. Andersson et al. BLOOD
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- Regulation of human NK-cell cytokine and chemokine production by target cell recognition
- (2009) C. Fauriat et al. BLOOD
- Education of human natural killer cells by activating killer cell immunoglobulin-like receptors
- (2009) C. Fauriat et al. BLOOD
- Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia
- (2009) G. Aue et al. HAEMATOLOGICA
- The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans
- (2009) Cameron S. Brandt et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells
- (2009) M. Carlsten et al. JOURNAL OF IMMUNOLOGY
- Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate
- (2009) A Poggi et al. LEUKEMIA
- Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells
- (2009) Laurent Boissel et al. LEUKEMIA RESEARCH
- Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo
- (2009) C. Sola et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Induction of MHC class I-related chain B (MICB) by 5-aza-2′-deoxycytidine
- (2008) Kai-Fu Tang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
- (2008) C. S. Tam et al. BLOOD
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- The immunodeficiency of chronic lymphocytic leukaemia
- (2008) A. D. Hamblin et al. BRITISH MEDICAL BULLETIN
- Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells
- (2008) Sonja Verheyden et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
- (2008) Karl-Johan Malmberg et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells
- (2008) Mareike Schmudde et al. CANCER LETTERS
- NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G
- (2008) G Maki et al. LEUKEMIA
- Natural killer cell–directed therapies: moving from unexpected results to successful strategies
- (2008) Magali Terme et al. NATURE IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now